DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
vom 29.06.2021, 01:11 Uhr
Bild: pixabay.com
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
29.06.2021 / 01:11
Vivoryon Therapeutics Provides Update on Financial Guidance
Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, today announced an update on its financial guidance. According to current estimates, the Company expects the recently signed regional licensing agreement with Simcere Pharmaceutical Group Ltd. to have an impact on Vivoryon s previously communicated cash-reach of Q3 2022, which is anticipated to be extended for at least three quarters until Q2 2023. A detailed update on anticipated working capital requirements and resulting timelines will be giv
Jack in Box : Hosts 2021 Virtual Investor Day (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Pensions guidance nudge skewed toward Pension Wise
professionalpensions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from professionalpensions.com Daily Mail and Mail on Sunday newspapers.
SRA lays ground for fee-capping in financial mis-selling claims
lawgazette.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawgazette.co.uk Daily Mail and Mail on Sunday newspapers.